Jazz Pharma Q3 revenue $940.7M (+12% YoY); raises FY guidance mid-point to $3.65B

Jazz Pharmaceuticals plc

2022-Q3 EPS reported $0.26 revenue$2,687,251,000

Q3 total revenue $940.7M, up 12% YoY; driven by Xywav, Epidiolex, and Rylaze demand.
Raises 2022 total revenue guidance mid-point to $3.65B, up from prior range.
Operating cash flow YTD $930M; cash $899.4M; net leverage ratio 2.9x.
More narcolepsy patients now on Xywav than Xyrem as of October 2022 milestone.
Pipeline progress: first patients enrolled in Phase 1 JZP815 and Phase 3 Epidyolex in Japan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.